These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 33004739)
1. CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. Cao Q; Bai P; Shi D; Liao J; Shi H; Xing Y; Chen K; Zhang X J Cancer Res Ther; 2020 Sep; 16(5):990-1001. PubMed ID: 33004739 [TBL] [Abstract][Full Text] [Related]
2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
4. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Zhou ZR; Liu SX; Zhang TS; Xia J; Li B Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458 [TBL] [Abstract][Full Text] [Related]
5. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028 [TBL] [Abstract][Full Text] [Related]
7. The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. Rizzo S; Galvano A; Pantano F; Iuliani M; Vincenzi B; Passiglia F; Spoto S; Tonini G; Bazan V; Russo A; Santini D Crit Rev Oncol Hematol; 2017 Dec; 120():227-233. PubMed ID: 29110971 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611 [TBL] [Abstract][Full Text] [Related]
9. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
10. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554 [TBL] [Abstract][Full Text] [Related]
11. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004 [TBL] [Abstract][Full Text] [Related]
12. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R; Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170 [TBL] [Abstract][Full Text] [Related]
13. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008 [TBL] [Abstract][Full Text] [Related]
14. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309 [TBL] [Abstract][Full Text] [Related]
15. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123 [TBL] [Abstract][Full Text] [Related]
16. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Di Lorenzo G; Sonpavde G; Pond G; Lucarelli G; Rossetti S; Facchini G; Scagliarini S; Cartenì G; Federico P; Daniele B; Morelli F; Bellelli T; Ferro M; De Placido S; Buonerba C Eur Urol Focus; 2018 Dec; 4(6):874-879. PubMed ID: 28753882 [TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Wei Z; Chen C; Li B; Li Y; Gu H Front Oncol; 2021; 11():732599. PubMed ID: 34513709 [TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291 [TBL] [Abstract][Full Text] [Related]
20. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. Scott LJ Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]